Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
28 9월 2023 - 1:50AM
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, will report financial results for the
second quarter fiscal year 2023 on Tuesday, October 3, 2023. The
Company has scheduled a conference call for that same day, Tuesday,
October 3, 2023 at 11:00am ET (4:00pm BST) to discuss the results
of the quarter.
Interested parties can access the call by
dialing:
US Toll Free: |
1-844-861-5499 |
International Toll: |
1-412-317-6581 |
Ireland Toll: |
014311269 |
Ireland Toll Free: |
1800932830 |
Please ask to be joined into the Trinity Biotech call. |
|
|
A simultaneous webcast of the call can be
accessed
at:https://event.choruscall.com/mediaframe/webcast.html?webcastid=gDGxHGGh
A replay of the call can be accessed until October
12, 2023 by dialing:
US Toll Free: |
1-877-344-7529 |
International Toll: |
1-412-317-0088 |
Canada Free Toll: |
1-855-669-9658 |
Replay Code: |
8784547 |
|
|
To access the replay using an international
dial-in number, please see the link
below:https://services.choruscall.com/ccforms/replay.html
A webcast of the call will be available for 30
days at:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=gDGxHGGh
Replays will be available 1 hour after the end of
the conference.
Certain statements made in this release that are
not historical are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
“estimate”, “project”, “intend”, “expect”, “believe” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve known and unknown risks
and uncertainties. Many factors could cause the actual results,
performance or achievements of Trinity Biotech to be materially
different from any future results, performance or achievements that
may be expressed or implied by such forward-looking statements,
including, but not limited to, the results of research and
development efforts, risks associated with the outbreak and global
spread of the coronavirus (COVID-19), the effect of regulation by
the U.S. Food and Drug Administration and other agencies, the
impact of competitive products, product development
commercialization and technological difficulties. For additional
information regarding these and other risks and uncertainties
associated with Trinity Biotech’s business, reference is made to
our reports filed from time to time with the U.S. Securities and
Exchange Commission. We undertake no obligation to update or revise
any forward-looking statements for any reason.
Trinity Biotech develops, acquires, manufactures
and markets diagnostic systems, including both reagents and
instrumentation, for the point-of-care and clinical laboratory
segments of the diagnostic market. The products are used to detect
infectious diseases and to quantify the level of Haemoglobin A1c
and other chemistry parameters in serum, plasma and whole blood.
Trinity Biotech sells direct in the United States, Germany, France
and the U.K. and through a network of international distributors
and strategic partners in over 75 countries worldwide. For further
information, please see the Company's website:
www.trinitybiotech.com.
Contact John Gillard Trinity
Biotech plc (353)-1-2769800
Joe Diaz Lytham Partners, LLC Investor Relations
(1)-602-889-9700 E-mail: investorrelations@trinitybiotech.com
Trinity Biotech (NASDAQ:TRIB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Trinity Biotech (NASDAQ:TRIB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024